KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Net Margin (2018 - 2025)

Historic Net Margin for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 0.6%.

  • Castle Biosciences' Net Margin fell 32500.0% to 0.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.55%, marking a year-over-year decrease of 55000.0%. This contributed to the annual value of 5.49% for FY2024, which is 316400.0% up from last year.
  • Latest data reveals that Castle Biosciences reported Net Margin of 0.6% as of Q3 2025, which was down 32500.0% from 5.29% recorded in Q2 2025.
  • Castle Biosciences' 5-year Net Margin high stood at 11.11% for Q4 2024, and its period low was 91.7% during Q1 2022.
  • Over the past 5 years, Castle Biosciences' median Net Margin value was 18.76% (recorded in 2021), while the average stood at 24.44%.
  • As far as peak fluctuations go, Castle Biosciences' Net Margin crashed by -729400bps in 2022, and later soared by 660000bps in 2024.
  • Over the past 5 years, Castle Biosciences' Net Margin (Quarter) stood at 25.68% in 2021, then tumbled by -109bps to 53.78% in 2022, then surged by 93bps to 3.9% in 2023, then soared by 385bps to 11.11% in 2024, then crashed by -105bps to 0.6% in 2025.
  • Its Net Margin was 0.6% in Q3 2025, compared to 5.29% in Q2 2025 and 29.38% in Q1 2025.